Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022

Disseminated Histoplasmosis in Persons with HIV/AIDS, Southern Brazil, 2010–2019

Rossana Patricia Basso, Vanice Rodrigues Poester, Jéssica Louise Benelli, David A. Stevens, and Melissa Orzechowski XavierComments to Author 
Author affiliations: Programa de Pós Graduação em Ciências da Saúde, Universidade Federal do Rio Grande, Rio Grande, Brazil (R.P. Basso, V.R. Poester, J.L. Benelli, M.O. Xavier); Hospital Universitário Dr. Miguel Riet Corrêa Jr., vinculado à Empresa Brasileira de Serviços Hospitalares, Rio Grande (R.P. Basso, J.L. Benelli); California Institute for Medical Research, San Jose, California, USA (D.A. Stevens); Stanford University Medical School, Stanford, California, USA (D.A. Stevens)

Main Article

Table 1

Clinical-epidemiologic data of 31 disseminated histoplasmosis cases diagnosed in persons living with HIV/AIDS, University Hospital Dr. Miguel Riet Corrêa Jr., Rio Grande, Brazil, 2010–2019

Variable Frequency, % (no./total no. participants)
M 74 (21/31)
26 (8/31)
Signs and symptoms
Weight loss 100 (31/31)
Fever (>37.8°C) 100 (31/31)
Respiratory: cough and/or dyspnea 100 (31/31)
Cutaneous: papular and/or ulcerated 52 (16/31)
Neurologic: disorientation, focal deficit, paresthesia, confusion, headache and/or hemiplegia 52 (16/31)
Digestive: abdominal distension and pain, diarrhea and/or nausea 81 (25/31)
Hepatomegaly 55 (17/31)
Splenomegaly 81 (25/31)
Generalized lymph node enlargement
35 (11/31)
Image exams
Interstitial lung pattern 55 (17/31)
Reticulonodular lung pattern 32 (10/31)
Pulmonary nodules 6 (2/31)
Mediastinal lymphadenopathy
26 (8/31)
Blood assays
Anemia 100 (31/31)
Inflammatory marker* 100 (31/31)
Liver damage marker† 84 (26/31)
Tissue injury marker‡ 87 (27/31)
74 (23/31)
HIV assays
CD4+ lymphocytes ≤100/mm3 71 (22/31)
CD4+ lymphocytes ≤50/mm3 48 (15/31)
HIV Viral load ≥50,000 copies
90 (26/29)
First choice antifungal treatment
None 3 (1/31)
Amphotericin B deoxycholate 81 (25/31)
16 (5/31)
Outcome after 12 months
Alive 65 (20/31)
Dead 35 (11/31)

*C-reactive protein increased. †Alkaline phosphatase increased. ‡Lactate dehydrogenase increased.

Main Article

Page created: January 27, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.